alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › ctad-task

ctad-task

2 studies tagged ctad-task, dated 2020-04-06 to 2025-04-18. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force 2025-04-18
  2. Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report 2020-04-06

Studies

2 studies carry this tag.

Date range

2020 to 2025

Top journals

  • The journal of prevention of Alzheimer's disease 2

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. The journal of prevention of Alzheimer's disease 2025-04-18 Drug development

    Following the recent approvals of anti-amyloid immunotherapies as "first-in-kind" disease-modifying agents for Alzheimer's disease (AD), there is an emerging emphasis in combination therapies, given the complex and multifactorial etiopathogenesis and pathophysiology of the disease.

  2. Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The journal of prevention of Alzheimer's disease 2020-04-06 Drug development

    While amyloid-targeting therapies continue to predominate in the Alzheimer's disease (AD) drug development pipeline, there is increasing recognition that to effectively treat the disease it may be necessary to target other mechanisms and pathways as well.

All topic tags with their study counts